Abstract PD1-09: Safety and efficacy results from the phase 1/2 study of U3-1402, a human epidermal growth factor receptor 3 (HER3)-directed antibody drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC)
Year: 2021
Type: conference-abstract
Source: Cancer Research
Authors: Ian Krop, Kan Yonemori, Shunji Takahashi, Kenichi Inoue, Takahiro Nakayama, Hiroji Iwata, Tatsuya Toyama, Yutaka Yamamoto, Masato Takahashi, Akihiko Osaki, Shigehira Saji, Yasuaki Sagara, Joyce O’Shaughnessy, Tiffany Traina, Shoichi Ohwada, Zhenhao Qi, Yang Qiu, Hiroshi Onuma, Om Sharma, Sabeen Mekan, Norikazu Masuda
Institutions: Dana-Farber Cancer Institute, National Cancer Centre Japan, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, Saitama Cancer Center, Osaka International Cancer Institute, Aichi Cancer Center, Nagoya City University, Kumamoto University Hospital, Sapporo National Hospital, Saitama Medical University, Fukushima Medical University Hospital, Sagara Hospital, Memorial Sloan Kettering Cancer Center, Daiichi-Sankyo (Japan), Osaka National Hospital
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3131429817